Colchicine treatment is unlikely to explain the hyper‐reactivity of FMF patients to PKC superfamily inhibitors since (i) we could recapitulate the findings in U937 cells; (ii) in vitro, colchicine reduces inflammasome activation (Gao et al, 2016; Park et al, 2016; Van Gorp et al, 2016); and (iii) three patients with Behcet's disease under colchicine were included in the disease control group and their monocytes did not display an FMF‐like phenotype. This evidence concerns the gene PRRT2 and Behcet disease.